{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:54:35Z","timestamp":1761515675365,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.4158\/ep10038.ed","type":"journal-article","created":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T21:04:40Z","timestamp":1269983080000},"page":"162-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["W(h)ither Metreleptin for Lipodystrophy and the Metabolic Syndrome?"],"prefix":"10.1016","volume":"16","author":[{"given":"Christos S.","family":"Mantzoros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP10038.ED_bb0010","series-title":"Endocrinology.","article-title":"Lipodystrophy syndromes","author":"Gao","year":"2010"},{"key":"10.4158\/EP10038.ED_bb0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N Engl J Med"},{"key":"10.4158\/EP10038.ED_bb0020","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1210\/jc.2002-021704","article-title":"Clinical review 159: human immunodeficiency virus\/highly active antiretroviral therapy-associated metabolic syndrome; clinical presentation, pathophysiology, and therapeutic strategies","volume":"88","author":"Leow","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP10038.ED_bb0025","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4158\/EP09154.RA","article-title":"Clinical classification and treatment of congenital and acquired lipodystrophy","volume":"16","author":"Chan","year":"2010","journal-title":"Endocr Pract"},{"key":"10.4158\/EP10038.ED_bb0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00125-009-1545-y","article-title":"Leptin therapy in lipodystrophy","volume":"53","author":"Savage","year":"2010","journal-title":"Diabetologia"},{"key":"10.4158\/EP10038.ED_bb0035","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1172\/JCI7901","article-title":"Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice","volume":"105","author":"Gavrilova","year":"2000","journal-title":"J Clin Invest"},{"key":"10.4158\/EP10038.ED_bb0040","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.cell.2008.09.036","article-title":"Identification of white adipocyte progenitor cells in vivo","volume":"135","author":"Rodeheffer","year":"2008","journal-title":"Cell"},{"key":"10.4158\/EP10038.ED_bb0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/43448","article-title":"Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy","volume":"401","author":"Shimomura","year":"1999","journal-title":"Nature"},{"key":"10.4158\/EP10038.ED_bb0050","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/90984","article-title":"The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity","volume":"7","author":"Yamauchi","year":"2001","journal-title":"Nat Med"},{"key":"10.4158\/EP10038.ED_bb0055","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1210\/jc.2002-020795","article-title":"Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy","volume":"88","author":"Addy","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP10038.ED_bb0060","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1086\/367859","article-title":"Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin","volume":"36","author":"Nagy","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.4158\/EP10038.ED_bb0065","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1210\/jc.2005-1545","article-title":"Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy","volume":"91","author":"Lee","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP10038.ED_bb0070","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/427697","article-title":"Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 \u00d7 2 factorial, randomized, double-blinded, placebo-controlled trial","volume":"40","author":"Gavrila","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.4158\/EP10038.ED_bb0075","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1210\/jc.2009-0340","article-title":"Whither recombinant human leptin treatment for HIV-associated lipoatrophy and the metabolic syndrome?","volume":"94","author":"Mantzoros","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP10038.ED_bb0080","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1210\/jc.2008-1588","article-title":"The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia","volume":"94","author":"Mulligan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP10038.ED_bb0085","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/EJE-08-0597","article-title":"r-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humans","volume":"160","author":"Brennan","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP10038.ED_bb0090","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11102-008-0092-8","article-title":"GH\/GHRH axis in HIV lipodystrophy","volume":"12","author":"Stanley","year":"2009","journal-title":"Pituitary"},{"key":"10.4158\/EP10038.ED_bb0095","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1210\/jc.2003-032140","article-title":"Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy","volume":"89","author":"Javor","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP10038.ED_bb0100","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.metabol.2006.11.010","article-title":"Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy","volume":"56","author":"Park","year":"2007","journal-title":"Metabolism"},{"key":"10.4158\/EP10038.ED_bb0105","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4158\/EP09155.RA","article-title":"Rationale for leptin-replacement therapy for severe lipodystrophy","volume":"16","author":"Oral","year":"2010","journal-title":"Endocr Pract"},{"key":"10.4158\/EP10038.ED_bb0110","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1172\/JCI0215693","article-title":"Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine\/metabolic dysfunction of human congenital leptin deficiency","volume":"110","author":"Farooqi","year":"2002","journal-title":"J Clin Invest"},{"key":"10.4158\/EP10038.ED_bb0115","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.4049\/jimmunol.174.6.3137","article-title":"Leptin in immunology","volume":"174","author":"Matarese","year":"2005","journal-title":"J Immunol"},{"key":"10.4158\/EP10038.ED_bb0120","doi-asserted-by":"crossref","first-page":"7745","DOI":"10.4049\/jimmunol.176.12.7745","article-title":"Leptin receptor expression and signaling in lymphocytes: kinetics during lymphocyte activation, role in lymphocyte survival, and response to high fat diet in mice","volume":"176","author":"Papathanassoglou","year":"2006","journal-title":"J Immunol"},{"key":"10.4158\/EP10038.ED_bb0125","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1210\/jc.2006-2864","article-title":"Pharmacokinetics of recombinant methionyl human leptin after subcutaneous administration: variation of concentration-dependent parameters according to assay","volume":"92","author":"Chan","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP10038.ED_bb0130","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/dia.2007.0294","article-title":"Immunogenicity of human and bovine insulin in type 1 diabetes mellitus patients","volume":"10","author":"Himanshu","year":"2008","journal-title":"Diabetes Technol Ther"},{"key":"10.4158\/EP10038.ED_bb0135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2337\/diacare.5.2.S119","article-title":"Development of IgE antibodies to human (recombinant DNA), porcine, and bovine insulins in diabetic subjects","volume":"5","author":"Fireman","year":"1982","journal-title":"Diabetes Care"},{"key":"10.4158\/EP10038.ED_bb0140","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2265.1993.tb00985.x","article-title":"Five-year follow-up of growth hormone antibodies in growth hormone deficient children treated with recombinant human growth hormone","volume":"38","author":"Massa","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP10038.ED_bb0145","doi-asserted-by":"crossref","first-page":"93","DOI":"10.7326\/0003-4819-152-2-201001190-00008","article-title":"Narrative review: the role of leptin in human physiology; emerging clinical applications","volume":"152","author":"Kelesidis","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.4158\/EP10038.ED_bb0150","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa040388","article-title":"Recombinant human leptin in women with hypothalamic amenorrhea","volume":"351","author":"Welt","year":"2004","journal-title":"N Engl J Med"},{"key":"10.4158\/EP10038.ED_bb0155","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/ncpendmet0196","article-title":"Drug insight: the role of leptin in human physiology and pathophysiology\u2014emerging clinical applications","volume":"2","author":"Brennan","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.4158\/EP10038.ED_bb0160","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1172\/JCI200317490","article-title":"The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men","volume":"111","author":"Chan","year":"2003","journal-title":"J Clin Invest"},{"key":"10.4158\/EP10038.ED_bb0165","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(05)66830-4","article-title":"Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa","volume":"366","author":"Chan","year":"2005","journal-title":"Lancet"},{"key":"10.4158\/EP10038.ED_bb0170","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1172\/JCI25977","article-title":"Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight","volume":"115","author":"Rosenbaum","year":"2005","journal-title":"J Clin Invest"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2041986X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2041986X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/J307GQ8K38295P74.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:50:28Z","timestamp":1761515428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2041986X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S1530891X2041986X"],"URL":"https:\/\/doi.org\/10.4158\/ep10038.ed","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2010,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"W(h)ither Metreleptin for Lipodystrophy and the Metabolic Syndrome?","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP10038.ED","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}